celecoxib has been researched along with Lymphoma, Non-Hodgkin in 3 studies
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
El Bary, NA | 1 |
Hashem, T | 1 |
Metwally, H | 1 |
Ghany, AA | 1 |
El Mageed, HA | 1 |
Buckstein, R | 1 |
Kerbel, RS | 1 |
Shaked, Y | 1 |
Nayar, R | 1 |
Foden, C | 1 |
Turner, R | 1 |
Lee, CR | 1 |
Taylor, D | 1 |
Zhang, L | 1 |
Man, S | 1 |
Baruchel, S | 1 |
Stempak, D | 1 |
Bertolini, F | 1 |
Crump, M | 1 |
Wang, W | 1 |
Kardosh, A | 1 |
Su, YS | 1 |
Schonthal, AH | 1 |
Chen, TC | 1 |
2 trials available for celecoxib and Lymphoma, Non-Hodgkin
Article | Year |
---|---|
A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclophospha | 2010 |
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclophosphamide; Disease Progressi | 2006 |
1 other study available for celecoxib and Lymphoma, Non-Hodgkin
Article | Year |
---|---|
Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model.
Topics: Animal Feed; Animals; Apoptosis; Burkitt Lymphoma; Celecoxib; Cell Line, Tumor; Central Nervous Syst | 2006 |